Overview

Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy

Status:
Completed

Trial end date:
2009-01-01

Target enrollment:

Participant gender:

Summary

To evaluate the effect of KW-3902IV, in addition to standard therapy, on the proportion of worsening heart failure and worsening renal function, and on the proportion of deaths or rehospitalizations for heart failure or worsening renal function, and to estimate and compare within-trial medical resource utilization and direct medical costs between subjects treated with KW 3902IV versus placebo.

Phase:

Phase 3

Details

Lead Sponsor:

NovaCardia, Inc.

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Rolofylline